Skip to main content
Mersana Therapeutics, Inc. logo

Mersana Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRSN ISIN · US59045L1061 LEI · 529900VWD5VDZ7PVOS22 US Manufacturing
Open in API
Filings indexed 700 across all filing types
Latest filing 2019-08-21 Regulatory Filings
Country US United States of America
Listing US MRSN

About Mersana Therapeutics, Inc.

https://www.mersana.com/

Mersana Therapeutics, Inc. is a clinical-stage company focused on discovering and developing life-changing antibody-drug conjugates (ADCs) for patients fighting cancer. The company utilizes its proprietary and differentiated ADC platforms, which incorporate both cytotoxic and immunostimulatory payloads, to develop its pipeline. These platforms are designed to customize and optimize ADCs, aiming to overcome the limitations of first-generation technologies by improving efficacy and tolerability. Mersana is advancing a portfolio of ADC candidates to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 20, 2019, by Mersana Therapeutics, Inc. It announces an event: the initiation of an expansion study of XMT-1536, and includes a press release as an exhibit. The document explicitly states that the information is being furnished and shall not be deemed filed for certain regulatory purposes. There are no financial statements or detailed financial data included. The document is a current report announcing a corporate event rather than a full financial report or earnings release. Given the nature of the filing and the content, this fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2019-08-21 English
10-Q
Interim / Quarterly Report Q2 2019
2019-08-08 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated August 8, 2019, by Mersana Therapeutics, Inc. It specifically states in Item 2.02 that it is furnishing a press release announcing financial results for the quarter ended June 30, 2019. The document itself is a current report that includes the press release as an exhibit but does not contain the full financial statements or detailed financial analysis. The length is 4136 characters, which is relatively short and consistent with a brief announcement rather than a full quarterly or annual report. According to the rules, such a document announcing quarterly financial results is classified as an Earnings Release (ER).
2019-08-08 English
8-K
Board/Management Information Classification · 100% confidence The document is a Form 8-K filed with the SEC, dated July 26, 2019, reporting the departure of a principal accounting officer and the appointment of a new one. The content focuses on management changes, including employment agreements and compensatory arrangements. There is no financial data or report content, but rather an announcement of changes in senior management positions. According to the filing definitions, announcements of changes in the company's board of directors or senior management fall under Board/Management Information (MANG). The document length is sufficient and contains detailed information about the management change, confirming it is not a brief announcement or a certification. Therefore, the appropriate classification is MANG with high confidence.
2019-07-26 English
4
Director's Dealing
2019-07-19 English
4
Director's Dealing
2019-07-19 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.